Latest news with #1stDetect
Business Upturn
01-08-2025
- Business
- Business Upturn
Astrotech Subsidiary 1st Detect Announces First Tracer 1000 NTD System Sale in Vietnam
AUSTIN, Texas , July 31, 2025 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC), a provider of next generation security screening and detection technologies based on Mass Spectrometry ('Mass Spec'), today announced the first sale and deployment of its TRACER 1000™ Narcotics Trace Detector ('TRACER 1000 NTD™') in Vietnam, by way of its subsidiary 1st Detect. This milestone marks a significant step in expanding the 1st Detect footprint across Southeast Asia and reinforces its commitment to enhancing narcotics trace detection inspection capabilities in global emerging markets. 'This first NTD system in Vietnam demonstrates Astrotech's growing presence in Asia and the increasing trust commercial and critical infrastructure operators are placing in our advanced technology,' said Tom Pickens, CEO of Astrotech Corp. 'We are honored to support Vietnam's security modernization efforts with next generation Mass Spec based trace detection and comprehensive library capabilities to deliver the accuracy, breadth and speed needed to counter the global narcotics trade.' 'The global narcotics and explosives trace detection market is estimated at more than $7 billion1 and growing rapidly, driven by a strong demand for innovation as law enforcement and public safety agencies combat an ever growing range of drugs and explosives,' said Pickens. '1st Detect offers a highly differentiated solution that not only provides the precision and reliability of Mass Spec analysis to clearly and accurately identify a substance, but also a virtually unlimited library capability to support the detection of new concerns and threats as they are identified in this fast-evolving marketplace.' TRACER 1000 NTD™, designed for confirmatory trace narcotics detection, enables security authorities to detect threats, contraband, and illicit materials with near-zero false alarm rate. 1st Detect's goal is to ensure that detection is future proof and gives authorities confidence in its results due to the highly precise nature of the Mass Spec technology. Astrotech Corp. remains committed to providing innovative, scalable security solutions to partners across the globe and looks forward to further collaborations in the region. About 1st Detect Based in Austin, Texas, 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. 1st Detect's explosive and narcotics trace detection feature a simple to use operating system designed specifically for security professionals. The TRACER 1000 ETD® and the TRACER 1000 NTD™ are rugged and portable to support security and detection in a variety of environments. For information, visit or contact [email protected]. About Astrotech Corporation Astrotech (Nasdaq: ASTC) is a mass spectrometry company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech's core technology to serve specialized markets: 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening applications. develops, manufactures, and markets trace detection systems for security and narcotics screening applications. AgLAB designs process analyzers tailored to the agriculture industry. designs process analyzers tailored to the agriculture industry. Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing. produces solutions for in-situ chemical process control in industrial manufacturing. BreathTech is advancing a breath analysis platform to detect volatile organic compounds (VOCs) associated with infections and critical health conditions. is advancing a breath analysis platform to detect volatile organic compounds (VOCs) associated with infections and critical health conditions. EN-SCAN, Inc. delivers portable, ruggedized environmental testing solutions that integrate gas chromatography and mass spectrometry for use in challenging field environments. Astrotech is headquartered in Austin, Texas. To learn more, visit . Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company's use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company's Securities and Exchange Commission filings including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Company Contact: Jennifer Cañas Chief Financial Officer, Astrotech Corporation (512) 485-9530
Yahoo
13-05-2025
- Business
- Yahoo
Astrotech Reports Third Quarter of Fiscal Year 2025 Financial Results
AUSTIN, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the 'Company' or 'Astrotech') reported its financial results for the third quarter of fiscal year 2025, which ended March 31, 2025. Thomas B. Pickens, III, Astrotech's Chairman, Chief Executive Officer and Chief Technology Officer, said, 'Our customizable, portable and field updatable mass spectrometry instruments have the potential to be a game changer in a growing list of large end markets such as airport security and cargo scanning, narcotics detection, environmental monitoring and chemical processing. I am very proud of our team's accomplishments, as we now have launched four product lines that we believe will expand our sales opportunities to potential customers from around the world. We have been serving airports worldwide with 1st Detect's explosive trace detection products in 15 countries having earned a valuable track record for delivering and maintaining our instruments.' Pickens continued, 'Our Pro-Control product line now includes in-situ process controls for automatic chemical manufacturing optimization. Decisions are progressing and many quotes are pending, and we are very encouraged with the testing we have completed with some of the largest chemical and petrochemical companies. We are currently focused on selling and marketing all our brands. With our newest product lines, the TRACER NTD, Pro-Control, and EN-SCAN we believe we have created great momentum in fiscal year 2025 and into fiscal year 2026 and are very excited about our future.' Financial Highlights & Recent Developments Fiscal year 2025 Q3 revenue of $534 thousand, compared to $50 thousand in fiscal year 2024 Q3, is comprised of TRACER 1000™ shipments, a government grant, and recurring consumable sales and maintenance services. On January 14, 2025, our 1st Detect subsidiary announced that it was awarded research and development contract 70RSAT24CB0000015 with the Department of Homeland Security ('DHS') to research, develop and mature the TRACER 1000 for DHS next generation explosives trace detection. On January 23, 2025, we announced that 1st Detect received a $429 thousand purchase order for its TRACER 1000™ ETDs from Intuitive Research and Technology Corporation, a TSA contractor, which was fulfilled and recognized as revenue during the three months ended March 31, 2025. On February 28, 2025, the Company announced that it had created a new wholly owned subsidiary, EN-SCAN, Inc., to manufacture and sell a new line of instruments built for environmental testing applications using its proprietary ATi Gas Chromatograph and Astrotech Mass Spectrometer Technology™. On March 10, 2025, we announced the TRACER 1000 NTD has been configured to screen for a range of synthetic opiates and novel psychoactive substances delivering accuracy and speed to counter the global drug crisis. Astrotech's consolidated balance sheet remains strong with $20.9 million in cash, cash equivalents and liquid investments to support the Company's completion of R&D projects and transition into a selling and marketing focused company. Cash, cash equivalents and liquid investments were $31.9 million at June 30, 2024. About Astrotech Corporation Astrotech (Nasdaq: ASTC) is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology through its wholly owned subsidiaries. 1st Detect develops, manufactures, and sells trace detectors for use in the security and narcotics detection market. AgLAB develops and sells process analyzers for use in the agriculture market. Pro-Control produces products for the in-situcontrol of the chemical manufacturing processes. BreathTech is developing a breath analysis tool to screen for volatile organic compounds that could indicate infections or critical conditions. EN-SCAN, Inc. develops advanced environmental testing and monitoring solutions, integrating gas chromatography and mass spectrometry technology in rugged, portable designs for rugged environments. Astrotech is headquartered in Austin, Texas. For information, please visit Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east and the COVID-19 pandemic, the Company's use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company's Securities and Exchange Commission filings including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Company Contact: Ryan Polk, Chief Financial Officer, Astrotech Corporation, (512) Contact: Matt Kreps, Managing Director, Darrow Associates, (214) 597-8200, mkreps@ Financial tables follow ASTROTECH CORPORATION AND SUBSIDIARIES Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share data) (Unaudited) Three Months Ended Nine Months Ended March 31, March 31, 2025 2024 2025 2024 Revenue $ 534 $ 50 $ 829 $ 1,590 Cost of revenue 297 42 428 867 Gross profit 237 8 401 723 Operating expenses: Selling, general and administrative 2,115 1,833 5,842 5,501 Research and development 1,989 1,708 6,375 5,158 Total operating expenses 4,104 3,541 12,217 10,659 Loss from operations (3,867 ) (3,533 ) (11,816 ) (9,936 ) Other income and expense, net 234 379 896 1,229 Net loss $ (3,633 ) $ (3,154 ) $ (10,920 ) $ (8,707 ) Weighted average common shares outstanding: Basic and diluted 1,665 1,633 1,663 1,632 Basic and diluted net loss per common share: Net loss per common share $ (2.18 ) $ (1.93 ) $ (6.57 ) $ (5.34 ) Other comprehensive loss, net of tax: Net loss $ (3,633 ) $ (3,154 ) $ (10,920 ) $ (8,707 ) Available-for-sale securities: Net unrealized gain 139 13 236 284 Total comprehensive loss $ (3,494 ) $ (3,141 ) $ (10,684 ) $ (8,423 ) ASTROTECH CORPORATION AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share and per share data) March 31, June 30, 2025 2024 (Unaudited) Assets Current assets Cash and cash equivalents $ 2,812 $ 10,442 Short-term investments 18,057 21,474 Accounts receivable 516 77 Contract Asset 7 — Inventory, net: Raw materials 2,296 2,038 Work-in-process 146 66 Finished goods 310 370 Prepaid expenses and other current assets 431 261 Total current assets 24,575 34,728 Property and equipment, net 2,486 2,763 Intangible asset, net 50 — Operating lease right-of-use assets, net 35 119 Other assets, net 346 30 Total assets $ 27,492 $ 37,640 Liabilities and stockholders' equity Current liabilities Accounts payable $ 616 $ 373 Payroll related accruals 928 1,174 Accrued expenses and other liabilities 882 754 Lease liabilities, current 66 227 Total current liabilities 2,492 2,528 Accrued expenses and other liabilities, net of current portion 193 232 Lease liabilities, net of current portion 55 73 Total liabilities 2,740 2,833 Commitments and contingencies (Note 14) Stockholders' equity Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at March 31, 2025, and June 30, 2024 — — Common stock, $0.001 par value, 250,000,000 shares authorized at March 31, 2025, and June 30, 2024, respectively; 1,704,269 and 1,712,045 shares issued at March 31, 2025, and June 30, 2024, respectively; 1,693,953 and 1,701,729 outstanding at March 31, 2025, and June 30, 2024, respectively 190,643 190,643 Treasury shares, 10,316 at March 31, 2025, and June 30, 2024, respectively (119 ) (119 ) Additional paid-in capital 83,109 82,480 Accumulated deficit (247,940 ) (237,020 ) Accumulated other comprehensive loss (941 ) (1,177 ) Total stockholders' equity 24,752 34,807 Total liabilities and stockholders' equity $ 27,492 $ 37,640 Sign in to access your portfolio
